Payors See 'Marginal' Return on Personalized Medicine Investment

The study showed "all stakeholder groups experience a positive ROI under certain conditions, although payors received only a marginal benefit and that is after six years."

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register quickly here for free access.